Mark
Lewis,
President and CEO
(Corporation)
Learn more...
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Kim Pate,
Senator
|
Senate of Canada
Subject Matter of the communication:
Health
Communication date:
2024-10-21
Posted date:
2024-10-23
Communication number:
371995-618949
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Marcus Powlowski,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2024-09-26
Posted date:
2024-10-15
Communication number:
371995-615569
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
william fassett,
Office Manager
|
House of Commons
-
Simon Wood,
Legislative Assistant
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2024-08-27
Posted date:
2024-09-16
Communication number:
371995-614604
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Sean Casey,
Member of Parliament
|
House of Commons
-
Robert Kitchen,
Member of Parlilament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2024-06-11
Posted date:
2024-08-15
Communication number:
371995-613244
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Jade Mallette,
Director of Parliamentary Affairs
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2024-04-17
Posted date:
2024-05-15
Communication number:
371995-603550
(amended from
371995-603473)
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Daniel MacDonald,
Director General, Drugs for Rare Diseases
| Strategic Policy Branch
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2024-03-22
Posted date:
2024-05-14
Communication number:
371995-603567
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Michelle Boudreau,
Associate Assistant Deputy Minister
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2024-03-22
Posted date:
2024-05-14
Communication number:
371995-603566
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Joanna Lam,
Policy and Regional Affairs Advisor
|
Indigenous Services Canada (ISC)
Subject Matter of the communication:
Health
Communication date:
2023-10-04
Posted date:
2023-11-15
Communication number:
371995-579255
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Dr. Stephen Ellis,
MP
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2023-08-03
Posted date:
2023-09-15
Communication number:
371995-574519
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Daniel Saad,
Senior Policy Advisor
| Policy and Cabinet Affairs
|
Prime Minister's Office (PMO)
Subject Matter of the communication:
Health
Communication date:
2023-06-29
Posted date:
2023-08-14
Communication number:
371995-574516
(amended from
371995-571382)
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Daniel macdonald,
Director General, Drugs for Rare Diseases
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2023-05-17
Posted date:
2023-06-15
Communication number:
371995-570188
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Shawn Driscoll,
Stakeholder Relations Advisor
|
House of Commons
-
Darren Hall,
Office of Leader of Opposition
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2023-05-05
Posted date:
2024-04-02
Communication number:
371995-566301
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Michelle Boudreau,
Executive Director, Office of Pharmaceutical Management Strategies
|
Health Canada (HC)
-
Dr. Stephen Ellis,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2023-04-24
Posted date:
2024-04-02
Communication number:
371995-566318
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Allison Haley,
Director of Parliamentary Affairs
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2023-04-20
Posted date:
2024-04-02
Communication number:
371995-566312
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Michelle Mujoomdar,
Director, Specialty Pharmaceuticals
|
Health Canada (HC)
-
Helen Gao,
Director of Policy
|
Indigenous Services Canada (ISC)
Subject Matter of the communication:
Health
Communication date:
2023-04-13
Posted date:
2024-04-02
Communication number:
371995-566309
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
renee bowers,
Manager and Sr Policy Analyst
|
Indigenous Services Canada (ISC)
-
Karen Fortin,
Director
|
Indigenous Services Canada (ISC)
Subject Matter of the communication:
Health
Communication date:
2023-04-11
Posted date:
2024-04-02
Communication number:
371995-566305
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Benoit Leduc,
Manager, Socio Economic Info
|
Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication:
Health
Communication date:
2023-04-04
Posted date:
2024-04-02
Communication number:
371995-566294
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Eric Costen ,
Senior ADM, Industry Sector
|
Innovation, Science and Economic Development Canada (ISED)
-
Darryl Patterson,
Director General, Life Sciences and Biomanufacturing Branch
|
Innovation, Science and Economic Development Canada (ISED)
-
Kasondra White,
Director, Biomanufacturing Branch, Strategy Directorate
|
Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication:
Science and Technology
Communication date:
2023-03-10
Posted date:
2023-04-15
Communication number:
371995-559405
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Daniel MacDonald,
Director General, Drugs for Rare Diseases
|
Health Canada (HC)
-
Michelle Boudreau,
Executive Director, Office of Pharmaceutical Management Strategies
|
Health Canada (HC)
-
Michelle Mujoomdar,
Director, Specialty Pharmaceuticals
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2022-12-06
Posted date:
2023-01-13
Communication number:
371995-553706
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Michelle Boudreau,
Executive Director, Office of Pharmaceutical Management Strategies
|
Health Canada (HC)
-
Michelle Mujoomdar,
Director, Specialty Pharmaceuticals
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2022-10-05
Posted date:
2022-10-12
Communication number:
371995-543118
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Zachary Nixon,
Senior Assistant, Stakeholder Relations & Regional Affairs
|
Global Affairs Canada (GAC)
Subject Matter of the communication:
Health
Communication date:
2022-10-03
Posted date:
2022-10-12
Communication number:
371995-543110
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Michelle Boudreau,
Executive Director
| Office of Pharmaceutical Management Strategies
|
Health Canada (HC)
-
Zachary Nixon,
Senior Special Assistant Stakeholder Relations and Regional Affairs
|
Global Affairs Canada (GAC)
Subject Matter of the communication:
Health
Communication date:
2022-09-13
Posted date:
2022-09-15
Communication number:
371995-541920
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Jamie Kippen,
Chief of Staff
| Minister's Office
|
Health Canada (HC)
Subject Matter of the communication:
Health
Communication date:
2022-07-15
Posted date:
2022-08-04
Communication number:
371995-539058
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Dr. Stephen Ellis,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2022-07-11
Posted date:
2022-08-04
Communication number:
371995-539059
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Jean-Yves Duclos,
Minister of Health
|
Health Canada (HC)
-
Adam Van Koeverden,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2022-07-11
Posted date:
2022-08-04
Communication number:
371995-539057
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Jamie Kippen,
Chief of Staff
| Minister's Office
|
Health Canada (HC)
-
Dr. Stephen Ellis,
Member of Parliament
|
House of Commons
-
Adam Van Koeverden,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2022-05-31
Posted date:
2022-06-28
Communication number:
371995-536368
View monthly communication report
-
Boehringer Ingelheim Canada Ltd.
In-house Corporation
Designated Public Office Holders who participated in the communication:
-
Sandenga Yeba,
Senior Policy Advisor
| Minister's Office
|
Health Canada (HC)
-
Ed Fast,
Member of Parliament
|
House of Commons
Subject Matter of the communication:
Health
Communication date:
2022-05-30
Posted date:
2022-06-28
Communication number:
371995-536375
View monthly communication report
